Kyowa Kirin Co., Ltd. (KYKOF)
OTC PINK OTC PINK Primary Summary
Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript
Kyowa Kirin Co., Ltd. (OTCPK:KYKOF) Q2 2025 Earnings Conference Call July 31, 2025 9:00 PM ET Company Participants Abdul Mullick - Representative Director, President & Chief Operating Officer Masashi Miyamoto - Chairman & CEO Motohiko Kawaguchi - CFO & Managing Executive Officer Takeyoshi Yamashita - Director, Executive VP & Chief Medical Officer Conference Call Participants Akinori Ueda - Goldman Sachs Group, Inc., Research Division Fumiyoshi Sakai - UBS Securities Japan Co., Ltd.
Kyowa Kirin Co., Ltd. (KYKOF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Kyowa Kirin Co., Ltd. ever had a stock split?
Kyowa Kirin Co., Ltd. Profile
| Health Care Providers & Services Industry | Healthcare Sector | Mr. Masashi Miyamoto Ph.D. CEO | OTC PINK Exchange | JP3256000005 ISIN |
| JP Country | 5,669 Employees | 31 Dec 2025 Last Dividend | - Last Split | - IPO Date |
Overview
Kyowa Kirin Co., Ltd., a subsidiary of Kirin Holdings Company, Limited, is a Japan-based pharmaceutical company with a global footprint. Established in 1949 and rebranded from Kyowa Hakko Kirin Co., Ltd. in June 2019, it focuses on the research, development, manufacturing, marketing, and import/export of pharmaceutical products. The company operates across key therapeutic areas including oncology, nephrology, central nervous system, and immunology, catering to markets in Japan, the United States, the Americas, Europe, Asia, and other regions worldwide. Through its collaboration with Amgen Inc., Kyowa Kirin is poised to co-develop and commercialize KHK4083, an innovative anti-OX40 fully human monoclonal antibody for treating atopic dermatitis, showcasing its commitment to advancing healthcare and treatment options globally.
Products and Services
- ALLELOCK: An antihistamine agent designed for patients suffering from various types of allergies, helping to relieve symptoms effectively.
- CONIEL: A calcium channel blocker used in the management of hypertension and angina pectoris, aiding in the regulation of blood pressure and heart conditions.
- Crysvita: A revolutionary recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23, utilized in specific bone disorders treatment.
- ESPO: A glycoprotein and human erythropoietin, contributing to the management of anemia associated with chronic renal failure.
- NESP: An erythropoiesis-stimulating agent, enhancing red blood cell production for patients with chronic kidney disease.
- GRAN / Peglasta / Neulasta: A human colony-stimulating factor aiming at the reduction of infection incidence in patients undergoing chemotherapy through febrile neutropenia prevention.
- LUMICEF: A biological treatment option for those suffering from moderate to severe plaque psoriasis, promoting skin health and relief.
- Moventig: A mu-opioid receptor antagonist for the specific treatment of opioid-induced constipation, ensuring comfort and wellbeing for patients on opioid therapy.
- Nouriast / Nourianz: An adenosine receptor antagonist employed in the management of Parkinson's disease, aiding in motor function improvement.
- ORKEDIA: An oral calcimimetic agent for the treatment of secondary hyperparathyroidism in patients undergoing dialysis.
- POTELIGEO: A humanized monoclonal antibody against CC chemokine receptor 4, utilized in certain cases of relapsed or refractory mycosis fungoides or Sézary syndrome.
- REGPARA: Administered for managing secondary hyperparathyroidism in patients with chronic kidney disease, maintaining calcium-phosphorus balance.
- Romiplate / Nplate: A genetically recombinant protein that stimulates the production of platelets through thrombopoietin receptors, crucial for patients with thrombocytopenia.
Contact Information
